Quanterix Corp. (QTRX) 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers Quanterix Corporation's Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Quanterix is a life sciences company focused on ultra-sensitive protein detection (Simoa technology) and spatial biology (acquired via Akoya Biosciences). The company operates as a single reportable segment, selling instruments, consumables, and services to research, academic, and biopharmaceutical customers globally. Key strategic developments in 2025 included the acquisitions of Akoya Biosciences (July 2025) and Emission, Inc. (January 2025), significant board and management transitions, and the submission of a 510(k) premarket notification for an Alzheimer's disease blood test.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $138.9 million | $137.4 million | +1.1% |
| Net Loss | $(107.2) million | $(38.5) million | Widened by $68.7 million |
| Gross Profit | $65.0 million | $83.1 million | -21.8% |
| Gross Margin | 46.8% | 60.5% | -13.7 pts |
| Operating Loss | $(125.5) million | $(52.6) million | Widened by $72.9 million |
| Cash & Cash Equivalents | $29.8 million | $56.7 million | -47.4% |
| Marketable Securities | $88.4 million | $232.4 million | -62.0% |
| Total Liquidity | $118.2 million | $289.1 million | -59.1% |
| Operating Cash Flow | $(77.2) million | $(35.2) million | Usage increased |
Note: The company reported no long-term debt as of December 31, 2025, having settled Akoya's debt upon acquisition.
Material Changes vs. Prior Period
- Acquisitions: The acquisition of Akoya Biosciences added $33.7 million in revenue but significantly increased operating expenses due to integration costs, amortization of acquired intangibles, and the assumption of Akoya's operating losses. The Emission acquisition added minimal revenue but incurred $10.0 million in milestone payments.
- Revenue Mix: Product revenue increased 17% to $92.9 million, driven by Akoya's spatial biology products. However, legacy Quanterix product revenue declined 11% due to macroeconomic headwinds. Service revenue decreased 14% to $44.2 million, impacted by the completion of a large Eli Lilly agreement in 2024.
- Impairment and Restructuring: The company recorded $15.7 million in impairment and restructuring costs in 2025, compared to none in 2024. This included a $6.4 million goodwill impairment related to the Emission acquisition and $8.0 million in restructuring costs (severance) to realize synergies from the Akoya deal.
- Profitability: Gross margin contracted from 60.5% to 46.8% primarily due to the lower-margin profile of the acquired Akoya business and increased cost of goods sold from new assay introductions.
Guidance, Outlook, and Risks
- Outlook: Management expects to achieve cash flow breakeven in 2026, contingent on meeting revenue and expense objectives. They anticipate revenue and bookings in 2026 to be consistent with 2025 levels.
- Strategic Milestones:
- Submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test for Alzheimer's disease (January 2026).
- Secured a CMS reimbursement rate of $897 for the LucentAD Complete test (November 2025).
- Launched an early access program for the next-generation "Simoa ONE" instrument.
- Key Risks:
- Macroeconomic Conditions: Reduced U.S. federal research funding, pharmaceutical R&D spending cuts, and import tariffs have constrained capital spending by customers.
- Integration Risks: Challenges in integrating Akoya's operations and realizing anticipated cost synergies ($85 million annualized target).
- Regulatory Uncertainty: Potential changes in FDA regulation of Laboratory Developed Tests (LDTs) and the impact of government policy on research funding.
- Liquidity: While current cash and marketable securities are sufficient for 12+ months, the company has a history of losses and may require additional capital if growth targets are not met.
Investor Verification Checklist
- Integration Progress: Verify the realization of the targeted $85 million in annualized cost savings from the Akoya acquisition and restructuring efforts.
- Regulatory Status: Monitor the FDA review timeline for the LucentAD Complete 510(k) submission and the potential impact of the terminated diagnostic development agreement with a biopharmaceutical customer (disclosed as a subsequent event).
- Cash Burn Rate: Assess the trajectory of operating cash flow to confirm the feasibility of the 2026 breakeven target given the $77.2 million cash burn in 2025.
- Revenue Sustainability: Evaluate the durability of the 17% product revenue growth, distinguishing between one-time acquisition impacts and organic growth in the legacy Simoa business.
- Goodwill Valuation: Review the remaining goodwill balance ($26.4 million) and the assumptions used in the impairment testing, given the volatility in the company's stock price and revenue outlook.